Pfizer ( PFE)

Drug: PF-02341066

Abstract No. 3

Indication: non-small cell lung cancer

Clinical Trial: Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer.

Presentation Time: Sunday, June 6. ASCO Plenary Session.

Notes: Pfizer gets a primetime slot at ASCO to highlight its research efforts into personalized cancer drugs. ASCO did not release the abstract Thursday night.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today